Clin Endosc.  2023 May;56(3):333-339. 10.5946/ce.2022.143.

Efficacy and safety of intragastric balloon for obesity in Korea

• Lee KG
• Nam SJ
• Choi HS
• Lee HL
• Yoon JH
• Park CH
• Kim KO
• Kim DH
• Kim JW
• Sohn W
• Jung SH
• Korean Research Group for Endoscopic Management of Metabolic Disorder and Obesity

• KMID: 2542461
• DOI: http://doi.org/10.5946/ce.2022.143

Abstract

Background/Aims
Intragastric balloon (IGB) is the only available endoscopic bariatric and metabolic therapy in Korea. End-ball (Endalis) has the longest history of clinical use among the IGBs available in Korea. However, little clinical data on this system have been reported. In this study, we aimed to evaluate the efficacy and safety of End-ball in Korea.
Methods
We performed a retrospective cohort study of patients who underwent IGB insertion (End-ball) from 2013 to 2019. Demographic and anthropometric data were collected. The efficacy and safety of IGB treatment were analyzed.
Results
In total, 80 patients were included. Mean age was 33.7 years and 83.8% were female. Initial body mass index was 34.48±4.69 kg/m2. Body mass index reduction was 3.72±2.63 kg/m2 at the time of IGB removal. Percent of total body weight loss (%TBWL) was 10.76%±6.76%. Percentage excess body weight loss was 43.67%±27.59%. Most adverse events were minor, and 71.4% of participants showed nausea, vomiting, or abdominal pain.
Conclusions
IGB treatment showed good efficacy and safety profile in Korean patients with obesity. In terms of %TBWL and percentage excess body weight loss, the efficacy was similar to that in the Western population.

Keyword

Bariatric; Endoscopic; Intragastric; Obesity; Weight loss

Figure

• 

Reference

1. Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet. 2011; 378:804–814.

2. Storm AC, Abu Dayyeh BK, Topazian M. Endobariatrics: a primer. Clin Gastroenterol Hepatol. 2018; 16:1701–1704.

3. Sullivan S, Edmundowicz SA, Thompson CC. Endoscopic bariatric and metabolic therapies: new and emerging technologies. Gastroenterology. 2017; 152:1791–1801.

4. McCarty TR, Thompson CC. The current state of bariatric endoscopy. Dig Endosc. 2021; 33:321–334.

5. Štimac D, Klobučar Majanović S, Belančić A. Endoscopic treatment of obesity: from past to future. Dig Dis. 2020; 38:150–162.

6. Choe Y, Kim JS, Kim BW. Short-term outcomes of intragastric balloon placement for obesity treatment. Korean J Helicobacter Up Gastrointest Res. 2020; 20:318–323.

7. Pak HJ, Choi HN, Lee HC, et al. Effects of intragastric balloon on obesity in obese Korean women for 6 months post removal. Nutr Res Pract. 2021; 15:456–467.

8. Kim BY, Kang SM, Kang JH, et al. 2020 Korean Society for the Study of Obesity guidelines for the management of obesity in Korea. J Obes Metab Syndr. 2021; 30:81–92.

9. Tai CM, Lin HY, Yen YC, et al. Effectiveness of intragastric balloon treatment for obese patients: one-year follow-up after balloon removal. Obes Surg. 2013; 23:2068–2074.

10. Ohta M, Kitano S, Kai S, et al. Initial Japanese experience with intragastric balloon placement. Obes Surg. 2009; 19:791–795.

11. Ganesh R, Rao AD, Baladas HG, et al. The bioenteric intragastric balloon (BIB) as a treatment for obesity: poor results in Asian patients. Singapore Med J. 2007; 48:227–231.

12. Mui WL, So WY, Yau PY, et al. Intragastric balloon in ethnic obese Chinese: initial experience. Obes Surg. 2006; 16:308–313.

13. Cho JH, Bilal M, Kim MC, et al. The clinical and metabolic effects of intragastric balloon on morbid obesity and its related comorbidities. Clin Endosc. 2021; 54:9–16.

14. Laing P, Pham T, Taylor LJ, et al. Filling the void: a review of intragastric balloons for obesity. Dig Dis Sci. 2017; 62:1399–1408.

15. Keren D, Rainis T. Intragastric balloons for overweight populations: 1 year post removal. Obes Surg. 2018; 28:2368–2373.

16. Marrero Torres RJ, Gregory F, Micames CG. Fluid-filled intragastric balloons are an effective and safe weight loss option across BMI and age ranges. Surg Endosc. 2022; 36:5160–5166.

17. ASGE Bariatric Endoscopy Task Force and ASGE Technology Committee, Abu Dayyeh BK, Kumar N, et al. ASGE Bariatric Endoscopy Task Force systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting endoscopic bariatric therapies. Gastrointest Endosc. 2015; 82:425–438.

18. Ribeiro IB, Kotinda APST, Sánchez-Luna SA, et al. Adverse events and complications with intragastric balloons: a narrative review (with video). Obes Surg. 2021; 31:2743–2752.

19. Neto MG, Silva LB, Grecco E, et al. Brazilian Intragastric Balloon Consensus Statement (BIBC): practical guidelines based on experience of over 40,000 cases. Surg Obes Relat Dis. 2018; 14:151–159.

20. Tak YJ, Lee SY. Anti-obesity drugs: long-term efficacy and safety: an updated review. World J Mens Health. 2021; 39:208–221.

21. Kim HO, Lee JA, Suh HW, et al. Postmarketing surveillance study of the efficacy and safety of phentermine in patients with obesity. Korean J Fam Med. 2013; 34:298–306.

22. Lewis KH, Fischer H, Ard J, et al. Safety and effectiveness of longer-term phentermine use: clinical outcomes from an electronic health record cohort. Obesity (Silver Spring). 2019; 27:591–602.

23. Mehta A, Shah S, Dawod E, et al. Impact of adjunctive pharmacotherapy with intragastric balloons for the treatment of obesity. Am Surg. 2021; 31348211038579.

24. Sioulas AD, Polymeros D, Kourikou A, et al. Intragastric balloon left in the stomach for more than a year: two case reports. Obes Facts. 2012; 5:436–439.

25. Genco A, Maselli R, Frangella F, et al. Intragastric balloon for obesity treatment: results of a multicentric evaluation for balloons left in place for more than 6 months. Surg Endosc. 2015; 29:2339–2343.